Последние новости из штаб-квартиры в Токио

Посмотреть все

• Сен. 2, 2021

  Transfer of FUJIFILM Toyama Chemical's Radiopharmaceutical Business to PeptiDream

• Авг. 31, 2021

  Launch of Therapeutic Radiopharmaceutical Product, Lutathera^® Injection targeting neuroendocrine tumors in Japan  (FUJIFILM Toyama Chemical)

• Июн. 29, 2021

  $850 Million USD (¥90 Billion Yen) investment in FUJIFILM Diosynth Biotechnologies to add additional development and manufacturing capacity

• Июн. 23, 2021

  Marketing Authorization Granted for Lutathera^® Injection in Japan
  - The first approval in Japan for peptide receptor radionuclide treatment drug, providing a new therapeutic option for neuroendocrine tumors  (FUJIFILM Toyama Chemical)

• Апр. 27, 2021

  Fujifilm sets its highest record with 23 products winning the internationally prestigious “iF Design Award”